Equities Analysts Offer Predictions for USNA FY2024 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Equities researchers at Sidoti Csr decreased their FY2024 earnings estimates for USANA Health Sciences in a research report issued to clients and investors on Wednesday, October 23rd. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings of $2.45 per share for the year, down from their prior forecast of $2.48. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.50 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2024 earnings at $0.49 EPS, Q1 2025 earnings at $0.73 EPS, Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.64 EPS, Q4 2025 earnings at $0.75 EPS, FY2025 earnings at $2.74 EPS, Q1 2026 earnings at $0.82 EPS, Q2 2026 earnings at $0.74 EPS, Q3 2026 earnings at $0.77 EPS and FY2026 earnings at $3.20 EPS.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million during the quarter, compared to analyst estimates of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. During the same period in the previous year, the business earned $0.59 EPS.

Other equities research analysts have also issued research reports about the stock. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th. DA Davidson decreased their price target on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday.

USANA Health Sciences Stock Performance

USANA Health Sciences stock opened at $36.81 on Thursday. The stock has a market cap of $701.27 million, a PE ratio of 11.47, a price-to-earnings-growth ratio of 1.15 and a beta of 0.89. The stock has a fifty day moving average of $37.90 and a 200 day moving average of $42.44. USANA Health Sciences has a one year low of $34.15 and a one year high of $54.81.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. grew its position in shares of USANA Health Sciences by 12.3% during the second quarter. American Century Companies Inc. now owns 159,782 shares of the company’s stock valued at $7,229,000 after purchasing an additional 17,460 shares in the last quarter. Pzena Investment Management LLC raised its holdings in shares of USANA Health Sciences by 24.4% during the 2nd quarter. Pzena Investment Management LLC now owns 976,633 shares of the company’s stock worth $44,183,000 after acquiring an additional 191,289 shares in the last quarter. Deerfield Management Company L.P. Series C grew its holdings in shares of USANA Health Sciences by 297.0% in the second quarter. Deerfield Management Company L.P. Series C now owns 29,742 shares of the company’s stock valued at $1,346,000 after purchasing an additional 22,251 shares in the last quarter. Panagora Asset Management Inc. increased its position in USANA Health Sciences by 143.1% in the second quarter. Panagora Asset Management Inc. now owns 28,881 shares of the company’s stock worth $1,307,000 after purchasing an additional 16,999 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in USANA Health Sciences by 5.6% during the second quarter. Bank of New York Mellon Corp now owns 97,375 shares of the company’s stock valued at $4,405,000 after purchasing an additional 5,205 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Gilbert A. Fuller sold 674 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Gilbert A. Fuller sold 674 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total transaction of $26,751.06. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John Turman Fleming sold 1,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares of the company’s stock, valued at $111,208.29. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,940 shares of company stock worth $311,670 over the last quarter. 0.33% of the stock is currently owned by corporate insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.